查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1457962

全球干细胞治疗市场：市场规模和占有率分析（依类型、细胞来源和应用）、工业需求预测（截至 2030 年）

Stem Cell Therapy Market Size and Share Analysis by Type, Cell Source, Application - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年全球干细胞治疗市场规模将达3.061亿美元，2030年将达9.108亿美元。

生长促进因子

市场成长的主要驱动力是骨科疾病、创伤、神经系统疾病和自体免疫疾病（狼疮、多发性硬化症、慢性阻塞性肺病、中风、帕金森氏症、肌萎缩侧索硬化症等）的患病率不断上升。

此外，随着对干细胞治疗的兴趣增加，对干细胞库的需求也在增加，预计这将成为未来市场扩张的驱动力。

此外，研究的进步和对个人化药物的日益关注也可能在未来几年推动该行业的发展。

异体干细胞疗法占有最大占有率

异体干细胞疗法将在2023年占据最大占有率，达到60%，预计2024年至2030年将以17%的速度成长。

这是因为推进此类治疗的临床试验数量正在增加。

同种异体移植的最大优点是没有肿瘤细胞污染移植物。移植物也由从捐赠者获得的免疫活性细胞组成，这可能会引发免疫移植物抗恶性肿瘤的作用。

北美地区收入占比最大

北美将成为依地区划分的市场领导者，到 2023 年，其占有率将达到 55%，并且在 10 年分析期结束时将显着增长。

这是因为该地区正在投资开发干细胞治疗方法。

亚太地区成长最快

亚太地区是成长最快的地区，其中中国是干细胞治疗的重点国家。

在本报告中，我们分析了全球干细胞治疗市场，包括市场的基本结构、最新情况、主要促进和抑制因素以及全球、依地区和主要国家的市场规模前景（价值基础） ，2017-2030）（年），依细胞类型、细胞来源和应用划分的详细趋势、当前市场竞争状况以及主要公司概况。

目录

第一章 调查范围

第二章研究方法

第3章执行摘要

第四章 市场指标

第五章 产业展望

  • 市场动态
    • 趋势
    • 促进因素
    • 抑制因素/课题
    • 促进/抑制因素影响分析
  • 新型冠状病毒感染（COVID-19）的影响
  • 波特五力分析

第六章 世界市场

  • 概述
  • 市场收入：依类型分类（2017-2030）
  • 市场收入：依电池来源分类（2017-2030）
  • 市场收入：依应用分类（2017-2030）
  • 市场收入：依地区（2017-2030）

第七章 北美市场

  • 概述
  • 市场收入：依类型分类（2017-2030）
  • 市场收入：依电池来源分类（2017-2030）
  • 市场收入：依应用分类（2017-2030）
  • 市场收入：依国家分类（2017-2030）

第八章欧洲市场

第九章亚太市场

第十章 拉丁美洲市场

第十一章 中东和非洲（MEA）市场

第十二章 美国市场

  • 概述
  • 市场收入：依类型分类（2017-2030）
  • 市场收入：依电池来源分类（2017-2030）
  • 市场收入：依应用分类（2017-2030）

第十三章 加拿大市场

第十四章 德国市场

第十五章 法国市场

第十六章 英国市场

第十七章 义大利市场

第十八章 西班牙市场

第十九章 日本市场

第20章 中国市场

第21章 印度市场

第22章澳洲市场

第23章 韩国市场

第24章 巴西市场

第25章 墨西哥市场

第26章 沙乌地阿拉伯市场

第27章南非市场

第28章 阿拉伯联合大公国（UAE）市场

第29章竞争格局

  • 市场参与者及其提供的产品/服务的列表
  • 主要企业竞争基准
  • 主要公司的产品基准
  • 近期策略发展状况

第三十章 公司简介

  • Smith & Nephew plc
  • MEDIPOST Co. Ltd.
  • Anterogen Co. Ltd.
  • CORESTEM Inc.
  • PHARMICELL Co. Ltd.
  • NuVasive Inc.
  • RTI Surgical Inc.
  • AlloSource
  • JCR Pharmaceutical Co. Ltd.
  • Takeda Pharmaceutical Company Limited

第31章附录

简介目录
Product Code: 12786

The size of the stem cell therapy market was USD 306.1 million in 2023, and it will touch USD 910.8 million in 2030, with a rate of 16.9% throughout the projection period.

Growth Drivers

The key factors responsible for the advance of the market are the growing incidence of orthopedic conditions, traumatic injuries, neurological ailments, and autoimmune diseases, such as lupus, multiple sclerosis, COPD, stroke, Parkinson's disease, and ALS.

Also, with the growing familiarity of stem cell therapy, the rising requirement for stem cell banking will power the market in the future.

Moreover, the growing advances in research and a rising emphasis on customized medications will power the industry in the years to come as well.

For example, in November 2022, USD 8 million was invested by the California Institute for Regenerative Medicine in the UC San Diego Alpha Stem Cell Clinic for allowing the latter to create more-efficient stem cell therapies for the diseases, which are difficult to treat.

Allogeneic Stem Cell Therapy had the Largest Share

The largest share of 60% was held by the Allogeneic stem cell therapy in 2023, and it will power at a rate of 17% during 2024-2030.

This is because of the growth in the count of clinical trials for the advance of these kinds of treatments.

The foremost advantage of allogeneic transplantation is that there is not any contaminating tumor cell in the graft. The graft also comprises immunocompetent cells resultant from a donor, which might initiate an immune graft-against-malignancy effect.

Autologous Therapy To Grow Significantly

The autologous therapy category will have a significant growth in the future due to the little risk of rejection of graft in this treatment. People requiring high-dose of chemotherapy and radiation are frequently transplanted with autologous stem cells for replacing the bone marrow damaged by the main treatment.

Furthermore, more than a few studies, conducted in recent times are focusing on autologous HSCT have shown optimistic results for secondary progressive multiple sclerosis. The method makes use of healthy blood stem cells from the own body of a person for replacing diseased cells.

North America to have Largest Revenue Share

North America was the leader of the regional market, with a share of 55%, in 2023, and it will grow significantly by the end of this decade.

This is due to the investment being provided for the development of stem cell therapies in this region.

For example, in September 2022, a gene-therapy-focused contract development and manufacturing company Forge Biologics Inc, publicized that it has acquired a total amount of USD 90 million in a Series C financing round co-led by Drive Capital and Aisling Capital, with another unrevealed strategic investor.

APAC Region To Grow the Fastest

Ther APAC region is observing the fastest-growth, with China being a key nation concentrating on stem cell therapy.

For example, OBiO Technology Corp. Ltd., a Shanghai-based gene-and-cell-therapy-focused CRO and CDMO in January 2023, publicized that the FDA has acknowledged its GMP plasmid drug master file filings for autologous and allogenic cell therapy and stem cell therapy products and helps in reducing the time taken in communication, assessment, and analysis of the filings for related therapeutics on part of the FDA.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by type
    • 1.4.2. Market size breakdown, by cell source
    • 1.4.3. Market size breakdown, by application
    • 1.4.4. Market size breakdown, by region
    • 1.4.5. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Type (2017-2030)
  • 6.3. Market Revenue, by Cell Source (2017-2030)
  • 6.4. Market Revenue, by Application (2017-2030)
  • 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Type (2017-2030)
  • 7.3. Market Revenue, by Cell Source (2017-2030)
  • 7.4. Market Revenue, by Application (2017-2030)
  • 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Type (2017-2030)
  • 8.3. Market Revenue, by Cell Source (2017-2030)
  • 8.4. Market Revenue, by Application (2017-2030)
  • 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Type (2017-2030)
  • 9.3. Market Revenue, by Cell Source (2017-2030)
  • 9.4. Market Revenue, by Application (2017-2030)
  • 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Type (2017-2030)
  • 10.3. Market Revenue, by Cell Source (2017-2030)
  • 10.4. Market Revenue, by Application (2017-2030)
  • 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Type (2017-2030)
  • 11.3. Market Revenue, by Cell Source (2017-2030)
  • 11.4. Market Revenue, by Application (2017-2030)
  • 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Type (2017-2030)
  • 12.3. Market Revenue, by Cell Source (2017-2030)
  • 12.4. Market Revenue, by Application (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Type (2017-2030)
  • 13.3. Market Revenue, by Cell Source (2017-2030)
  • 13.4. Market Revenue, by Application (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Type (2017-2030)
  • 14.3. Market Revenue, by Cell Source (2017-2030)
  • 14.4. Market Revenue, by Application (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Type (2017-2030)
  • 15.3. Market Revenue, by Cell Source (2017-2030)
  • 15.4. Market Revenue, by Application (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Type (2017-2030)
  • 16.3. Market Revenue, by Cell Source (2017-2030)
  • 16.4. Market Revenue, by Application (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Type (2017-2030)
  • 17.3. Market Revenue, by Cell Source (2017-2030)
  • 17.4. Market Revenue, by Application (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Type (2017-2030)
  • 18.3. Market Revenue, by Cell Source (2017-2030)
  • 18.4. Market Revenue, by Application (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Type (2017-2030)
  • 19.3. Market Revenue, by Cell Source (2017-2030)
  • 19.4. Market Revenue, by Application (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Type (2017-2030)
  • 20.3. Market Revenue, by Cell Source (2017-2030)
  • 20.4. Market Revenue, by Application (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Type (2017-2030)
  • 21.3. Market Revenue, by Cell Source (2017-2030)
  • 21.4. Market Revenue, by Application (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Type (2017-2030)
  • 22.3. Market Revenue, by Cell Source (2017-2030)
  • 22.4. Market Revenue, by Application (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Type (2017-2030)
  • 23.3. Market Revenue, by Cell Source (2017-2030)
  • 23.4. Market Revenue, by Application (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Type (2017-2030)
  • 24.3. Market Revenue, by Cell Source (2017-2030)
  • 24.4. Market Revenue, by Application (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Type (2017-2030)
  • 25.3. Market Revenue, by Cell Source (2017-2030)
  • 25.4. Market Revenue, by Application (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Type (2017-2030)
  • 26.3. Market Revenue, by Cell Source (2017-2030)
  • 26.4. Market Revenue, by Application (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Type (2017-2030)
  • 27.3. Market Revenue, by Cell Source (2017-2030)
  • 27.4. Market Revenue, by Application (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Type (2017-2030)
  • 28.3. Market Revenue, by Cell Source (2017-2030)
  • 28.4. Market Revenue, by Application (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Smith & Nephew plc
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. MEDIPOST Co. Ltd.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Anterogen Co. Ltd.
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. CORESTEM Inc.
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. PHARMICELL Co. Ltd.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. NuVasive Inc.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. RTI Surgical Inc.
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. AlloSource
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. JCR Pharmaceutical Co. Ltd.
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary
  • 30.10. Takeda Pharmaceutical Company Limited
    • 30.10.1. Business overview
    • 30.10.2. Product and service offerings
    • 30.10.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports